We are live on ! Find out more
ALT icon

Altimmune

102 hedge funds and large institutions have $296M invested in Altimmune in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more call options, than puts

Call options by funds: $8.43M | Put options by funds: $5.15M

34% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 29

0.95% less ownership

Funds ownership: 82.66%81.71% (-0.95%)

14% less funds holding

Funds holding: 118102 (-16)

21% less capital invested

Capital invested by funds: $375M → $296M (-$79.1M)

44% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 34

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
102
Holders Change
-16
Holders Change %
-13.56%
% of All Funds
1.57%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
19
Increased
39
Reduced
29
Closed
34
Calls
$8.43M
Puts
$5.15M
Net Calls
+$3.28M
Net Calls Change
-$16.3M

ALT Hedge Fund Activity: Q4 2021 in Review

102 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q4 2021, worth a combined $296M — down 21% from $375M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of ALT and 19 opened new positions — a net loss of 15 holders — while 29 trimmed existing stakes and 39 added.

The largest buyer was Nuveen, adding an estimated $15.8M. The largest seller was VR Adviser, exiting entirely with an estimated $43M sold.

  • 102 institutional investors held Altimmune (ALT) as of Q4 2021, down from 118 in Q3 2021.
  • Funds reported $296M of Altimmune stock for Q4 2021, down 21% quarter-over-quarter.
  • 19 funds opened new Altimmune positions in Q4 2021 and 34 closed out, a net change of -15 holders.
  • The largest Altimmune buyer in Q4 2021 was Nuveen, an estimated $15.8M added.
  • The largest Altimmune seller in Q4 2021 was VR Adviser, an estimated $43M sold.

Based on aggregated 13F filings for Q4 2021.